NASDAQ:PTE Polarityte Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Polarityte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.05 -0.05 (-4.55 %) (As of 09/21/2020 03:59 PM ET) Add Compare Share Today's Range$1.05Now: $1.05▼$1.1650-Day Range$1.02MA: $1.30▼$1.6352-Week Range$0.78Now: $1.05▼$4.80Volume6,902 shsAverage Volume855,987 shsMarket Capitalization$40.68 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingPolarityte has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.40, Polarityte has a forecasted upside of 315.1% from its current price of $1.06.Amount of Analyst CoveragePolarityte has only been the subject of 2 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesPolarityte has received 124 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPolarityte has received 110 “underperform” votes. (Add your “underperform” vote.)Community SentimentPolarityte has received 52.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Polarityte and other stocks. Vote “Outperform” if you believe PTE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PTE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPolarityte does not currently pay a dividend.Dividend GrowthPolarityte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Polarityte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,516.00 in company stock.Percentage Held by InsidersOnly 8.38% of the stock of Polarityte is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of Polarityte is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Polarityte are expected to grow in the coming year, from ($1.24) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Polarityte is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Polarityte is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolarityte has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTE Previous Symbol CUSIPN/A CIKN/A Webwww.polarityte.com Phone385-237-2279Debt Debt-to-Equity Ratio0.16 Current Ratio3.83 Quick Ratio3.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.65 million Price / Sales7.20 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.74Profitability EPS (Most Recent Fiscal Year)($3.70) Net Income$-92,490,000.00 Net Margins-1,152.56% Return on Equity-179.96% Return on Assets-120.61%Miscellaneous Employees153 Outstanding Shares38,741,000Market Cap$40.68 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $1.05 -0.05 (-4.55 %) (As of 09/21/2020 03:59 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PTE News and Ratings via Email Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter. Polarityte (NASDAQ:PTE) Frequently Asked Questions How has Polarityte's stock been impacted by Coronavirus (COVID-19)? Polarityte's stock was trading at $1.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTE stock has decreased by 1.9% and is now trading at $1.05. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Polarityte? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte. When is Polarityte's next earnings date? Polarityte is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Polarityte. How were Polarityte's earnings last quarter? Polarityte Inc (NASDAQ:PTE) released its earnings results on Thursday, August, 6th. The company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.07. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $0.85 million. Polarityte had a negative return on equity of 179.96% and a negative net margin of 1,152.56%. During the same quarter in the previous year, the company posted ($0.92) EPS. View Polarityte's earnings history. What guidance has Polarityte issued on next quarter's earnings? Polarityte updated its third quarter 2020 Pre-Market earnings guidance on Monday, September, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.2 million, compared to the consensus revenue estimate of $2.85 million. What price target have analysts set for PTE? 5 brokerages have issued 12 month price targets for Polarityte's shares. Their forecasts range from $3.00 to $6.00. On average, they expect Polarityte's share price to reach $4.40 in the next year. This suggests a possible upside of 319.0% from the stock's current price. View analysts' price targets for Polarityte. Are investors shorting Polarityte? Polarityte saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 3,360,000 shares, an increase of 17.9% from the July 15th total of 2,850,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 2.3 days. Approximately 14.1% of the company's stock are short sold. View Polarityte's Short Interest. Who are some of Polarityte's key competitors? Some companies that are related to Polarityte include Fennec Pharmaceuticals (FENC), INmune Bio (INMB), LogicBio Therapeutics (LOGC), Lineage Cell Therapeutics (LCTX), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), Gritstone Oncology (GRTS), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), La Jolla Pharmaceutical (LJPC), Champions Oncology (CSBR), Solid Biosciences (SLDB), Windtree Therapeutics (WINT), Verona Pharma (TARA) and Gamida Cell (GMDA). View all competitors. What other stocks do shareholders of Polarityte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include BioNano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania R.E.I.T. (PEI), Matinas BioPharma (MTNB), Cannabics Pharmaceuticals (CNBX), Novan (NOVN), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), OrganiGram (OGI) and AEterna Zentaris (AEZS). Who are Polarityte's key executives? Polarityte's management team includes the following people: Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)Mr. Paul Elliot Mann, Exec. OfficerMr. Richard Hague, Pres & COO (Age 60)Mr. Jacob Alexander Patterson, Interim Chief Financial Officer What is Polarityte's stock symbol? Polarityte trades on the NASDAQ under the ticker symbol "PTE." Who are Polarityte's major shareholders? Polarityte's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (1.95%), FMR LLC (1.95%), Advisor Group Holdings Inc. (0.46%), Jane Street Group LLC (0.24%), Bernardo Wealth Planning LLC (0.21%) and Levin Capital Strategies L.P. (0.10%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Jeffrey Hansen Dyer, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin. View institutional ownership trends for Polarityte. Which institutional investors are selling Polarityte stock? PTE stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., FMR LLC, FMR LLC, and Advisor Group Holdings Inc.. Company insiders that have sold Polarityte company stock in the last year include Cameron J Hoyler, David B Seaburg, Denver Lough, Jeffrey Hansen Dyer, Paul Elliot Mann, Rainer M Erdtmann, and Richard Hague. View insider buying and selling activity for Polarityte. Which institutional investors are buying Polarityte stock? PTE stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Verition Fund Management LLC, and Bernardo Wealth Planning LLC. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, and Peter A Cohen. View insider buying and selling activity for Polarityte. How do I buy shares of Polarityte? Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Polarityte's stock price today? One share of PTE stock can currently be purchased for approximately $1.05. How big of a company is Polarityte? Polarityte has a market capitalization of $40.68 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe. What is Polarityte's official website? The official website for Polarityte is www.polarityte.com. How can I contact Polarityte? Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
